R
Redpin Therapeutics
We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system
About Redpin Therapeutics
Redpin Therapeutics operates at the intersection of biotechnology and neuroscience, focusing on the development of chemogenetic therapies. The company leverages pioneering research to create a platform that uses anti-smoking drugs to control neurons. This innovative approach has potential applications in both research and clinical settings. Redpin Therapeutics primarily serves pharmaceutical companies, research institutions, and healthcare providers. The market it operates in is the rapidly growing field of gene therapy and neurotechnology. The business model revolves around licensing its technology, partnering with pharmaceutical companies for drug development, and providing specialized research services. Revenue is generated through licensing fees, research grants, and collaborative agreements.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- New York City, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 56.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2022 | $0 | — | Kriya Therapeutics | ↗ |
| SERIES AEquity / VC | Jan 2021 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Redpin Therapeutics is 250 monthly website visits, down 28.6% over the last three months. Redpin Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Redpin Therapeutics in the New York City ecosystem
The Redpin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
4BIO Capital
Takeda Ventures
Arkin Capital
New York Ventures
Other known investors4 additional known investors
Kriya Therapeutics
Rockefeller University
A-Squared Ventures
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Redpin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Redpin Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








